Evotec SE (ADR)
General ticker "EVO" information:
- Sector: Health Care
- Industry: Life Sciences Tools & Services
- Capitalization: $1.4B (TTM average)
Evotec SE (ADR) follows the US Stock Market performance with the rate: 4.3%.
Estimated limits based on current volatility of 1.7%: low 3.16$, high 3.29$
Factors to consider:
- Total employees count: 203 as of 2007
- Price in estimated range
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [2.58$, 5.67$]
- 2025-12-31 to 2026-12-31 estimated range: [2.31$, 5.15$]
Financial Metrics affecting the EVO estimates:
- Positive: with PPE of -7.8 at the end of fiscal year the price was low
- Negative: negative Operating income
- Positive: -14.38 < Investing cash flow per share per price, % of -4.65
- Negative: negative Industry operating cash flow (median)
- Positive: 41.86 < Shareholder equity ratio, % of 49.81 <= 63.39
- Positive: 0.33 < Operating cash flow per share per price, % of 1.19
- Positive: Industry inventory ratio change (median), % of -1.41 <= -0.15
Short-term EVO quotes
Long-term EVO plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | €751.45MM | €781.43MM | €796.97MM |
| Operating Expenses | €730.60MM | €828.93MM | €939.49MM |
| Operating Income | €20.85MM | €-47.51MM | €-142.52MM |
| Non-Operating Income | €-174.81MM | €-33.09MM | €-51.45MM |
| Interest Expense | €13.15MM | €11.74MM | €11.70MM |
| R&D Expense | €76.64MM | €68.53MM | €50.86MM |
| Income(Loss) | €-153.96MM | €-80.59MM | €-193.98MM |
| Taxes | €21.70MM | €3.32MM | €2.10MM |
| Profit(Loss)* | €-175.66MM | €-83.91MM | €-196.08MM |
| Stockholders Equity | €1,187.18MM | €1,119.91MM | €952.52MM |
| Inventory | €29.82MM | €30.89MM | €31.12MM |
| Assets | €2,257.25MM | €2,252.47MM | €1,912.50MM |
| Operating Cash Flow | €205.81MM | €36.44MM | €18.22MM |
| Capital expenditure | €181.35MM | €216.00MM | €132.24MM |
| Investing Cash Flow | €-412.80MM | €-13.29MM | €-71.19MM |
| Financing Cash Flow | €-58.15MM | €71.96MM | €-161.42MM |
| Earnings Per Share** | €-0.50 | €-0.24 | €-0.55 |
| Ordinary share to ADR | 2.00x | 2.00x | 2.00x |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.